World-first psilocin binge eating disorder trial reveals improvement in all patients

Swinburne University of Technology and Entropy Neurodynamics’ world-first IV-infused psilocin binge eating disorder trial has led to improvement in all participants.

Following completion of just two TRP-8803 treatments, 50 per cent of patients did not experience a single binge-eating episode during the entire 84-day follow-up period.

This pilot trial resulted in a 73 per cent reduction in binge eating episodes for the six treatment resistant participants, who also experienced a 50 per cent reduction in anxiety, 42 per cent reduction in depression, and a 61 per cent improvement in quality of life.

Swinburne Director of Clinical Trials and project lead Professor Susan Rossell is thrilled to have maintained the success of the trial at the four-week mark.

“Changing the lives of these six participants is a huge feat,” she says.

“These were patients who had lived with binge eating disorder for as long as 20 years and who had previously failed treatment. Before entering the study, patients averaged 2.3 binge eating episodes every week. 

“We hope that we can replicate these benefits across the millions of people suffering this debilitating disorder around the world, and potentially even the millions of others experiencing other treatment resistant mental illnesses who may have given up hope.”

Entropy Neurodynamics Limited CEO Jason Carroll says these 12-week results are particularly encouraging.

“For us, durability is critical,” he says.

“We are not seeking to develop another medicine that patients need to take every day. We are investigating whether a limited number of precision-controlled psychedelic treatments can produce a clinically meaningful benefit that persists long after dosing has finished.

“These are early data from a small study, but the regulatory direction and the clinical evidence we are generating are increasingly aligned. We believe these results provide increasing clinical validation of our precision-controlled approach and materially strengthen the clinical rationale for continued development of TRP-8803.”

Swinburne and Entropy Neurodynamic are currently seeking participants for a second cohort who will trial a shorter TRP-8803 infusion treatment regimen to further optimise treatment efficiency and clinical scalability.